Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with non‐Hodgkin lymphoma
Authors:
Open Access
- 3 November 2010
- Vol. 116 (22) , 5279-5289
Abstract
BACKGROUND.: The current study was conducted to evaluate the association between colony‐stimulating factor (CSF) use and the risk of developing therapy‐related myelodysplastic syndromes or acute myeloid leukemia (t‐MDS/AML) among a large cohort of elderly patients with non‐Hodgkin lymphoma (NHL) who were treated with chemotherapy.METHODS.: A total of 13,203 NHL patients were identified from the Surveillance, Epidemiology, and End Results‐Medicare database who were diagnosed from 1992 through 2002. Patients were followed from their initial chemotherapy date until the date they were diagnosed with t‐MDS/AML, death, or last follow‐up (October 31, 2006), whichever occurred first.RESULTS.: Overall, 40% (n = 5266) of patients received CSF. During the follow‐up period (median follow‐up, 2.9 years [range, 1‐14.7 years]), 272 (5.2%) patients who were treated with CSF developed t‐MDS/AML, compared with 230 (2.9%) patients who did not (P < .0001, log‐rank test). The 5‐year incidence of t‐MDS/AML for patients receiving CSF was 14.1 per 1000 person‐years compared with 8.3 per 1000 person‐years for patients not receiving CSF. In a multivariable Cox regression analysis adjusted for gender, histology, stage, comorbidities, radiotherapy, and chemotherapy agent, CSF use was found to be independently associated with a 53% increased risk of t‐MDS/AML (hazard ratio [HR], 1.53; 95% confidence interval [95% CI], 1.26‐1.84). The observed association between CSF use and t‐MDS/AML persisted across histologic subgroups (ie, diffuse large B‐cell lymphoma, follicular lymphoma, and others). Patients who received both CSF and antimetabolite chemotherapy were found to have a 2.5‐fold increased risk of t‐MDS/AML (HR, 2.49; 95% CI, 1.91‐3.26) compared with patients who received neither agent.CONCLUSIONS.: The current study, which to our knowledge is the first large population‐based study published to date, demonstrated that the administration of CSF among elderly NHL patients receiving chemotherapy was associated with an increased risk of t‐MDS/AML, although the absolute risk was low. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 30 references indexed in Scilit:
- Chemotherapy-induced Secondary MalignanciesJournal of Infusion Nursing, 2003
- Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatmentBlood, 2003
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project ExperienceJournal of Clinical Oncology, 2003
- Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin’s Lymphoma PatientsJournal of Clinical Oncology, 2003
- Risk of Leukemia Following Treatment for Non-Hodgkin's LymphomaJNCI: Journal of the National Cancer Institute, 1994
- Therapy-related myeloid leukaemiaThe Lancet, 1990
- Impact on second malignancy risk of the combined use of radiation and chemotherapy for lymphomasCancer, 1990
- Second malignancies in children treated for non-Hodgkin's lymphoma and T-cell leukaemia with the UKCCSG regimensBritish Journal of Cancer, 1987
- Risk of Acute Nonlymphocytic Leukemia and Preleukemia in Patients Treated with Cyclophosphamide for Non-Hodgkin's LymphomasAnnals of Internal Medicine, 1985